Can I Take Saw Palmetto with AOD-9604?

What Is AOD-9604 and How Does It Work?

AOD-9604 is a synthetic 16-amino-acid peptide corresponding to the C-terminal region (positions 176 to 191) of human growth hormone. It was originally developed by Metabolic Pharmaceuticals to target fat metabolism without the insulin-sensitizing or IGF-1-raising activity of full-length GH. Research in rodent models showed dose-dependent reductions in adipose tissue, particularly visceral fat, through beta-adrenergic receptor stimulation and lipolytic signaling [1].

Receptor Activity and Metabolic Pathway

AOD-9604 appears to bind beta-3 adrenergic receptors, promoting lipolysis while sparing anabolic GH pathways. Because it does not raise IGF-1 to a meaningful degree, it avoids the insulin resistance associated with supraphysiologic GH exposure [1]. Animal data from a 2001 study published in the American Journal of Physiology demonstrated that a 500-mcg/kg intraperitoneal dose reduced body weight in obese rodents by approximately 50% more than vehicle controls over 15 days [2].

Regulatory and Compounding Status

The FDA has not approved AOD-9604 for any indication in humans. A Phase II trial (Metabolic Pharmaceuticals, 2001 to 2004) was discontinued before confirmatory Phase III data were generated. Clinicians who prescribe it today do so through 503A compounding pharmacies, which operate under USP standards but are not subject to the same approval pathway as marketed drugs [3].

What AOD-9604 Does Not Do

AOD-9604 does not meaningfully inhibit 5-alpha-reductase. It does not alter androgen metabolism. It is not metabolized through hepatic CYP450 isoforms in the way small-molecule drugs are, because peptides are primarily degraded by circulating and tissue proteases [4]. That distinction matters when evaluating potential interactions with saw palmetto.

What Is Saw Palmetto and What Are Its Active Mechanisms?

Saw palmetto (Serenoa repens) is a standardized liposterolic extract derived from the fruit of the American dwarf palm. It is most commonly used for benign prostatic hyperplasia (BPH) and androgenic alopecia. The 2022 American Urological Association BPH guideline lists saw palmetto as an option some patients choose, though the guideline notes that evidence for symptom improvement is inconsistent across trials [5].

5-Alpha-Reductase Inhibition

The primary pharmacodynamic action of saw palmetto is competitive inhibition of both isoforms of 5-alpha-reductase (5-AR1 and 5-AR2), the enzyme that converts testosterone to dihydrotestosterone (DHT). A 2012 randomized trial published in JAMA (N=306, 72 weeks) found that saw palmetto at doses up to 960 mg daily did not significantly reduce lower urinary tract symptoms compared with placebo (change in AUA symptom score: 2.20 vs. 2.99 points, P = 0.26) [6]. That trial is important because it also confirmed the extract's safety profile at supratherapeutic doses.

Antiplatelet and Anticoagulant Effects

Saw palmetto extracts contain free fatty acids that inhibit cyclooxygenase (COX) and thromboxane A2 synthesis, producing mild antiplatelet activity. Case reports have described increased bleeding time in patients undergoing surgery who had been taking saw palmetto at standard doses (160 mg twice daily) for more than four weeks [7]. The Natural Medicines database categorizes saw palmetto as having a "minor" potential interaction with anticoagulant and antiplatelet agents [8].

CYP450 Metabolism

In vitro studies suggest saw palmetto extract may weakly inhibit CYP2D6 and CYP3A4 at concentrations higher than those typically achieved with standard 160-mg dosing [9]. That inhibition is unlikely to be clinically relevant at therapeutic doses for most patients, but it becomes relevant if a patient is simultaneously taking a narrow-therapeutic-index drug metabolized by those enzymes.

Is There a Direct Interaction Between Saw Palmetto and AOD-9604?

No published study has directly examined the combination of saw palmetto and AOD-9604 in humans. That absence of data is itself meaningful: it tells clinicians that no known metabolic pathway links the two agents in a way that would produce a predictable pharmacokinetic interaction.

Why a Pharmacokinetic Interaction Is Unlikely

AOD-9604 is a peptide. Peptides are cleaved by aminopeptidases, endopeptidases, and carboxypeptidases in plasma and peripheral tissues. They are not substrates for CYP2D6 or CYP3A4, the isoforms saw palmetto mildly inhibits [4]. Because neither agent shares a metabolic enzyme, the absorption, distribution, or clearance of one is not expected to be changed by the other.

Where Pharmacodynamic Overlap Could Matter

Pharmacodynamic interactions involve two agents acting on the same physiologic process and either amplifying or blunting each other's effect. Saw palmetto and AOD-9604 act on different pathways: saw palmetto modulates androgen metabolism and platelet function; AOD-9604 modulates beta-3 adrenergic signaling and lipolysis. No shared downstream target creates a documented pharmacodynamic conflict between them specifically.

The one theoretical concern sits at a distance from both agents: if a patient is simultaneously using AOD-9604, saw palmetto, and a prescription anticoagulant such as warfarin or apixaban, the mild antiplatelet activity of saw palmetto could compound bleeding risk. That is a saw-palmetto-plus-anticoagulant interaction, not a saw-palmetto-plus-AOD-9604 interaction. AOD-9604 itself has no known effect on coagulation.

5-Alpha-Reductase and AOD-9604: No Overlap

Saw palmetto's 5-AR inhibition is pharmacologically irrelevant to AOD-9604 because AOD-9604 does not depend on androgen signaling for its lipolytic mechanism. Clinicians sometimes prescribe AOD-9604 to patients who are also on finasteride (5 mg, FDA-approved for BPH) or dutasteride (0.5 mg, FDA-approved for BPH) without documented interaction reports, suggesting the 5-AR pathway is genuinely orthogonal to AOD-9604's mechanism [10].

Who Should Be Most Cautious About Taking Both?

Most patients taking AOD-9604 as a compounded peptide for body composition are not at elevated risk from also taking saw palmetto. Specific subpopulations deserve closer attention.

Patients on Concurrent Anticoagulation

Any patient taking warfarin, apixaban, rivaroxaban, or heparin-based products and who wants to add saw palmetto should have a baseline INR or anti-Xa level documented before starting. The prescribing clinician should recheck bleeding markers after four weeks on saw palmetto at the standard 160-mg twice-daily dose. The AOD-9604 component of the regimen does not independently change this calculation, but it is part of the full medication list a prescriber must review.

Patients with Hormone-Sensitive Conditions

Saw palmetto's 5-AR inhibition lowers DHT, which matters for patients with prostate cancer, hormone-sensitive breast tissue conditions, or those on testosterone replacement therapy (TRT). A 2020 review in Endocrine Reviews noted that DHT reduction through 5-AR inhibition is relevant in patients managing androgenic side effects of exogenous testosterone [11]. If AOD-9604 is part of a broader TRT or peptide stack, the attending clinician must account for saw palmetto's androgen-modulating effect as a separate variable.

Pre-Operative Patients

The American Society of Anesthesiologists recommends stopping herbal supplements with antiplatelet properties, including saw palmetto, at least seven days before elective surgery [12]. AOD-9604 should also be discussed with the anesthesia team, particularly because there is no published pharmacokinetic data on its clearance from plasma at standard subcutaneous doses in surgical patients.

Dosing and Timing: What the Data Support

No clinical trial has established an optimal dose-separation window between saw palmetto and AOD-9604 because no trial has examined both agents simultaneously. The following framework is built from each agent's individual pharmacokinetic data.

AOD-9604 Pharmacokinetics

AOD-9604 reaches peak plasma concentration approximately 15 to 30 minutes after subcutaneous injection based on early Phase I pharmacokinetic reports filed with the Therapeutic Goods Administration (TGA) in Australia during Metabolic Pharmaceuticals' trial program. Its half-life in plasma is estimated at less than two hours, meaning active plasma concentrations are largely resolved within six hours of a 300-mcg subcutaneous dose [13].

Saw Palmetto Pharmacokinetics

Standardized saw palmetto extract (160 mg, liposterolic extract) reaches peak serum fatty acid concentrations approximately two hours after oral dosing. Steady-state concentrations build over two to four weeks of daily use because the lipophilic active components partition into adipose tissue [9]. This means saw palmetto's biological effect on 5-AR and platelet function is essentially continuous once steady state is reached, not pulsatile.

Practical Recommendation

Because there is no shared metabolic competition, dose separation has no pharmacological rationale for reducing any interaction between these two specific agents. Patients who inject AOD-9604 in the morning can take saw palmetto at their preferred time without concern about timing-based interaction. The clinician's attention should focus on the full medication list, not the clock.

Monitoring Recommendations for Patients Taking Both

A structured monitoring plan addresses the realistic risks associated with each agent individually and the remote possibility of additive effects.

Baseline Labs Before Starting the Combination

• Complete blood count (CBC) with platelet count to establish baseline platelet function
• PSA (prostate-specific antigen) if the patient is male and over 40, because saw palmetto may modestly lower PSA, potentially masking prostate pathology [14]
• Lipid panel, because AOD-9604 was associated with a small reduction in total cholesterol in the Phase II trial data
• INR or anti-Xa level if the patient takes a prescription anticoagulant

Follow-Up at 30 and 90 Days

PSA should be rechecked at 90 days in men over 40. Any unexplained bruising, prolonged bleeding from cuts, or blood in urine should prompt immediate clinical evaluation and temporary discontinuation of saw palmetto pending workup. AOD-9604 does not alter coagulation markers, so persistent bleeding abnormalities after stopping saw palmetto would require separate investigation.

Signs That Should Prompt Discontinuation

Stop saw palmetto and contact the prescribing clinician if the patient experiences: rectal bleeding, hemoptysis, or a significant bruise from minor trauma. These are not expected side effects of AOD-9604 at 300 mcg daily, and their appearance in a patient taking saw palmetto aligns with the supplement's known antiplatelet mechanism [7].

What Clinicians Who Prescribe AOD-9604 Should Know About Saw Palmetto Co-Use

Patients pursuing compounded peptide protocols, including AOD-9604, frequently self-select into heavy supplement stacks. A 2020 survey published in JAMA Internal Medicine found that 52% of U.S. Adults used at least one dietary supplement, and that disclosure to physicians occurred in fewer than 35% of cases [15]. That disclosure gap creates clinical risk not because saw palmetto and AOD-9604 specifically interact, but because undisclosed supplements obscure a patient's full pharmacological picture.

What to Ask Patients at the Intake Visit

Clinicians prescribing AOD-9604 through a 503A compounding pharmacy should ask directly:

1. Are you taking any supplements marketed for prostate health or hair loss (which includes saw palmetto, finasteride, and DHT-blocking agents)?
2. Are you taking any blood thinners, fish oil above 2 g daily, or NSAIDs regularly?
3. Have you had any surgical procedures planned in the next 90 days?

These three questions surface the most clinically relevant risks from saw palmetto co-use without requiring the clinician to enumerate every possible supplement.

Documentation Standard

The prescribing clinician should document saw palmetto co-use in the patient's active medication list, the dose (typically 160 mg twice daily or 320 mg once daily), the duration of use, and the reason for use (BPH, androgenic alopecia, or patient-directed). Regulatory guidance from the FDA for 503A compounding pharmacies requires a valid patient-specific prescription and adequate clinical justification [3]. The supplement list is part of that clinical record.

Saw Palmetto Efficacy: Is It Worth Taking Alongside AOD-9604?

This question matters because patients combining the two agents presumably have specific goals. AOD-9604 is prescribed primarily for visceral fat reduction and body composition. Saw palmetto is most commonly used for BPH symptom management or to reduce scalp DHT in androgenic alopecia.

BPH Symptom Relief

The CAMUS trial (N=369, 72 weeks) found no significant reduction in AUA symptom scores with saw palmetto 320 mg daily versus placebo (mean score change: 0.04 points difference, 95% CI: 1.49 to 1.57) [6]. Prescribing clinicians should inform patients seeking saw palmetto for BPH that evidence for symptom relief is weak at standard doses, and that FDA-approved 5-AR inhibitors (finasteride 5 mg, dutasteride 0.5 mg) have substantially more supporting data [10].

Androgenic Alopecia

A small 2002 randomized trial (N=26, 21 to 48 years old) published in the Journal of Alternative and Complementary Medicine found that 60% of patients treated with saw palmetto 200 mg plus beta-sitosterol 50 mg daily reported improvement in hair loss after approximately five months, versus 11% in the placebo group [16]. These findings have not been replicated in large trials. Patients on TRT who add AOD-9604 and are also trying to address androgenic alopecia should discuss whether topical minoxidil or oral finasteride (1 mg) would provide better-evidenced options than saw palmetto.

Key Takeaways for Patients Already Taking Both

Patients who are already taking saw palmetto and AOD-9604 together do not need to stop one or both immediately. The combination is not known to cause direct harm. Three things should happen without delay.

First, tell your prescribing clinician about every supplement you take, including saw palmetto, the dose, and how long you have been taking it.

Second, if you take any prescription blood thinners, get a bleeding-time or INR check within the next two weeks.

Third, if you are a man over 40, make sure your PSA has been checked within the past 12 months, because saw palmetto at 160 to 320 mg daily may lower PSA by 5% to 10%, according to a 2003 analysis in Urology, which could partially mask rising PSA values [14].